The Food and Drug Administration has approved the first ever gene therapy for inherited hearing loss, a one-time treatment developed by Regeneron Pharmaceuticals that has proven life-changing for children born deaf due to a mutation in a gene called OTOF, which the ear needs to transmit sound signals to the brain. In a clinical trial of 20 children, 16 showed meaningful improvements in hearing within five months, and five of the 12 followed for at least 11 months had their hearing essentially restored to normal. One mother whose two-year-old son received the treatment said she had been told her child might only ever hear with external technology, and that watching him hear on his own felt miraculous. Before this approval, cochlear implants were the only option available to children with this form of genetic deafness.
What makes the news even more remarkable is Regeneron’s announcement that the therapy will be provided free of charge to eligible patients in the United States, a striking departure from the norm in gene therapy, where one-time treatments for rare conditions are typically priced in the millions of dollars per patient. The therapy works by delivering a working copy of the faulty OTOF gene directly to the ear through a surgical procedure, replacing the missing instructions the body needs to produce the otoferlin protein and allowing sound to travel from the cochlea to the brain. Only around 50 babies are born in the United States each year with this specific genetic variant, making it rare, but the FDA commissioner called the approval a significant milestone for genetic hearing loss, and researchers say the approach opens a clear door to developing gene therapies for other inherited forms of deafness as well. A pediatric ear surgeon who worked on the trial said the hearing it restores is on 24 hours a day and does not rely on batteries.
Source: https://edition.cnn.com/2026/04/23/health/fda-gene-therapy-inherited-deafness-regeneron
